United Therapeutics Corporation or Ionis Pharmaceuticals, Inc.: Who Invests More in Innovation?

Biotech Giants' R&D Race: Ionis vs. United Therapeutics

__timestampIonis Pharmaceuticals, Inc.United Therapeutics Corporation
Wednesday, January 1, 2014241751000242549000
Thursday, January 1, 2015322292000245098000
Friday, January 1, 2016344320000147600000
Sunday, January 1, 2017374644000264600000
Monday, January 1, 2018414604000357900000
Tuesday, January 1, 20194660000001182600000
Wednesday, January 1, 2020535000000357700000
Friday, January 1, 2021643000000540100000
Saturday, January 1, 2022833000000322900000
Sunday, January 1, 2023899625000408000000
Monday, January 1, 2024901530000
Loading chart...

Unleashing the power of data

Innovation Investment: A Tale of Two Biotech Giants

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Ionis Pharmaceuticals, Inc. and United Therapeutics Corporation have been at the forefront of this race. From 2014 to 2023, Ionis Pharmaceuticals consistently outpaced United Therapeutics in R&D investment, with an average annual increase of approximately 12%. Notably, in 2023, Ionis allocated nearly 900 million dollars to R&D, marking a 270% increase from 2014. In contrast, United Therapeutics' R&D spending peaked in 2019, with a significant 1.18 billion dollars, but has since seen fluctuations. This trend highlights Ionis' steady commitment to innovation, while United Therapeutics shows a more variable investment pattern. As the biotech industry evolves, these financial commitments underscore the strategic priorities of each company in driving future breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025